This paper aims to solve an optimal control problem using three different numerical approaches applied to a mathematical model of HCV. To evaluate the efficiency of the perturbation iteration method, the results are compared with those obtained using the direct method and an approach integrating fuzzy logic. The findings, derived from MATLAB implementation, align well with experimental data and demonstrate the response of interferon and ribavirin to the dynamics of uninfected and infected hepatocytes in a patient suffering from HCV. The numerical methods used show similar trends; however,   the perturbation method has an advantage over the others due to the regularity of the curves it produces. Consequently, it represents a valuable approach for solving the optimal control problem. In particular, it provides the optimal trajectories for uninfected and infected hepatocytes while ensuring their effective performance.

hepatitis C virus, uninfected hepatocytes, infected hepatocytes, ribavirin, pegylated IFN, numerical simulation

Received: October 2, 2024; Accepted: December 10, 2024; Published: December 20, 2024

How to cite this article: Mahamat Saleh DAOUSSA HAGGAR and Jean Marie Ntaganda, Efficacy of the perturbation iteration method in testing the response of hepatitis C virus treatment on the dynamics of uninfected and infected hepatocytes, Universal Journal of Mathematics and Mathematical Sciences 21(1) (2025), 13-37. https://doi.org/10.17654/2277141725002

This Open Access Article is Licensed under Creative Commons Attribution 4.0 International License

References
[1] S. M. Feinstone, A. Z. Kapikian, R. H. Purcell, H. J. Alter and P. V. Holland, Transfusion associated hepatitis not due to viral hepatitis type A or B, N. Engl. J. Med. 292 (1975), 767-770.
[2] M. Houghton, Discovery of the hepatitis C virus, Liver Int. 29 (2009), 82-88.
[3] Q. L. Choo et al., Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science 244 (1989), 359-362. doi:10.1126/science.2523562 PMID:2523562.
[4] Jens Bukh, The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control, Journal of Hepatology 65 (2016), S2-S1.
[5] M. J. Alter, Epidemiology of hepatitis C virus infection, World J. Gastroenterol. 13 (2007), 2436-2441.
[6] J. P. Messina, I. Humphreys, A. Flaxman, A. Brown, G. S. Cooke, O. G. Pybus and E. Barnes, Global distribution and prevalence of hepatitis C virus genotypes, Hepatology 61 (2015), 77-87.
[7] P. Simmonds et al., Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology 42 (2005), 962-973. doi:10.1002/hep.20819 PMID:16149085.
[8] J. M. Pawlotsky, Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens, Gastroenterology 151 (2016), 70-86.
[9] J. Torresi, D. Johnson and H. Wedemeyer, Progress in the development of preventive and therapeutic vaccines for hepatitis C virus, J. Hepatol. 54 (2011), 1273-1285.
[10] A. Takaoka and H. Yanai, Interferon signalling network in innate defence, Cell Microbiol. 8 (2006), 907-922.
[11] K. Li et al., Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF, Proc. Natl. Acad. Sci. USA 102 (2005), 2992-2997.
[12] P. Andreone et al., ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment- experienced patients with HCV genotype 1b infection, Gastroenterology 147 (2014), 359-365.
[13] A. U. Neumann, N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden and A. S. Perelson, Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- therapy, Science 282 (1998), 103-107.
[14] N. M. Dixit, J. E. Layden-Almer, T. J. Layden and A. S. Perelson, Modelling how ribavirin improves interferon response rates in hepatitis C virus infection, Nature 432 (2004), 922-924.
[15] H. Dahari, A. Lo, R. M. Ribeiro and A. S. Perelson, Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy, J. Theoret. Biol. 247 (2007), 371-381.
[16] S. Lenhart and J. T. Workman, Optimal Control Applied to Biological Models, 1st ed., Chapman and Hall/CRC, 2007. https://doi.org/10.1201/9781420011418.
[17] S. P. Chakrabarty and H. R. Joshi, Optimally controlled treatment strategy using interferon and ribavirin for hepatitis C, Journal of Biological Systems 17(1) (2009), 97-110.
[18] S. P. Chakrabarty, Optimal efficacy of ribavirin in the treatment of hepatitis C, Optimal Control Applications and Methods 30(6) (2009), 594-600.
[19] N. K. Martin, B. Ashley, A. B. Pitcher, P. Vickerman, A. Vassal and M. Hickman, Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users, PLoS One 6(8) (2011), e22309.
[20] Jean Marie Ntaganda, Mathematical modelling of hepatitis C virus dynamics response to therapeutic effects of interferon and ribavirin, Int. J. Computational Biology and Drug Design 13(2) (2020), 169-180.
[21] Y. Aksoy and M. Pakdemirli, New perturbation-iteration solutions for Bratu-type equations, Comput. Math. Appl. 59(8) (2010), 2802-2808.
[22] M. Pakdemirli, Y. Aksoy and H. Boyaci, A new perturbation-iteration approach for first order differential equations, Math. Comput. Appl. 16(4) (2011), 890-899.
[23] M. Pakdemirli, Review of the perturbation-iteration method, Math. Comput. Appl. 18(3) (2013), 139-151.
[24] Jean Marie NTAGANDA, Mahamat Saleh DAOUSSA HAGGAR and Angelique Dukunde, Fuzzy logic strategy implemented on an optimal control problem of hypoxemic hypoxia tissue blood dioxide carbon exchange: cardiovascular-respiratory system response to exercise, International Journal of Science Academic Research 3(5) (2022), 3816-3822.